FDA Brief

Warning letters Drugs

FDA warning letter to

Glicerinas Industriales, S.A. de C.V.

High riskIssued Jun 13, 2022Posted Jun 21, 2022Center for Drug Evaluation and Research | CDER

Glicerinas Industriales refused a pre-announced FDA inspection; FDA calls its glycerin drugs adulterated and placed firm on Import Alert 66-79.

What happened

FDA notified GLINSA of a planned drug manufacturing inspection for May 16 to May 20, 2022. The firm refused the pre-announced inspection during a February 24, 2022 phone call and after written notice received by UPS on March 23, 2022. FDA says the firm supplies glycerin drug components to finished drug manufacturers for the U.S. market and that glycerin contaminated with diethylene glycol has caused lethal poisonings.

What FDA found

  1. The firm refused or limited a pre-announced FDA inspection, so its drugs are adulterated under the FD&C Act.

    section 501(j) of the FD&C Act, 21 U.S.C. 351(j)

What FDA wants

Respond in writing within 15 working days to CDER-OC-OMQ-Communications@fda.hhs.gov, identifying FEI 3016420687 and ATTN: Bill Fowler. You may provide additional information for FDA to consider and/or request an FDA inspection.

Who should pay attention

  • finished drug manufacturers buying glycerin from this supplier
  • US brands and distributors using glycerin in drug products
  • importers and suppliers of pharmaceutical ingredients

This is a summary. Read the original letter on fda.gov.

Glicerinas Industriales, S.A. de C.V.'s FDA history

  1. Glicerinas Industriales, S.A. de C.V.

    FDA warned Glicerinas Industriales over CGMP failures in repackaged glycerin and propylene glycol, including DEG/EG testing and particulate contamination.

    High risk

Full company page

Similar letters to other companies

  1. Kellin Chemicals Co., Ltd. - Zhangjiagang

    Kellin Chemicals' API site refused FDA inspection, so FDA calls its drugs adulterated.

    High risk
  2. New Life Pharma LLC

    New Life Pharma made unapproved semaglutide and tirzepatide sterile vials without sterility controls and refused FDA access to some areas.

    High risk
  3. Jagsonpal Pharmaceuticals Limited

    Jagsonpal Pharmaceuticals cited for API CGMP and listing failures after Indian inspection, leading to US import alert.

    High risk
  4. Tianjin Darentang Jingwanhong Pharmaceutical Co., Ltd.

    FDA cited Tianjin Darentang Jingwanhong Pharmaceutical for limiting a drug inspection and manufacturing violations at its China plant.

    High risk